Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Focuses On COVID-19 Antibody Approach After Year Of Vaccine Headwinds

Jab Sales Strong Despite Hurdles

Executive Summary

During its fourth quarter earnings call, the UK-based major expressed hopes that its prophylactic antibody approach would fare better after its COVID-19 jab faced several obstacles in developed markets last year.

You may also be interested in...



AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio

The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.

AZ's COVID-19 Antibody Combo Protects For Longer But Access Issues Persist

AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.

AstraZeneca’s Pangalos: Cultural Diversity Is Key To Educating Scientists

Mene Pangalos talked to Scrip about the importance of cultural diversity in a lab setting, pushing the frontiers on public-private partnerships and redoubling efforts on gene editing.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel